I'll speak to the Health Canada portion, but it is part of a broader strategy. NRCan has some funding to deal with some of the technical issues. CIHR is looking at some clinical trials, to decide long-term questions about the research. For Health Canada's part, there were several things we wanted to know after the isotope crisis. We realized that during the shortages there were groups of people who used different isotopes or different alternatives to isotopes. We wanted to make sure that we had a mechanism to develop policies and protocols to establish when the various alternatives are preferable, and how the various outcomes compare.
So I would say it's in the medium term. It's not the longest-term research that CIHR is funding. It's more applied research—investigating, working with experts, to understand what we can learn from other countries about the effective and appropriate use of isotopes.